QTTB
Q32 Bio Inc.
$12.64
-0.47%
$214.3M
No data for this timeframe.
Vol
Market Cap$214.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders25 funds
Inst. Value$13.9M
Inst. Activity3 buys / 1 sells
Insider Activity2B / 3S
Insider Net $$19.9M
SEC Reports6
Recent Activity
Jun 4, 2026
short_volume
Short Volume: QTTB — 69.8% short (0.5M / 0.7M)
Short: 486,236 | Exempt: 0 | TRF Vol: 696,739 | Short Ratio: 69.8% | Off-exchange volume (dark pool
Jun 2, 2026
SEC
Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May 28, 2026, for a tot
CLUSTER — Impact 8/10
May 28, 2026
Insider
ORBIMED ADVISORS LLC bought 1,250,000 shares
Director @ $8.00 ($10.0M)
May 28, 2026
Insider
Xu Diyong bought 1,250,000 shares
Director @ $8.00 ($10.0M)
May 5, 2026
SEC
Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025, driven by lower R&D
8-K — Impact 4/10
Apr 24, 2026
SEC
Q32 Bio Inc. has filed an additional prospectus supplement to raise up to $75 million through its at-the-market (ATM) of
8-K — Impact 6/10
Feb 25, 2026
Insider
Morrison Jodie Pope sold 9,896 shares
CEO @ $4.51 ($44.7K)
Inst.
BlackRock, Inc. — ADD
86,147 shares ($553.1K)
Price Targets
$14.25
+12.7% upside
Buy
Current $12.64
Low $10.00
Median $13.50
High $20.00
4 analysts
$10.00
$20.00
Analyst Ratings
3Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | Mizuho | INITIATE | Outperform |
| May 18, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 25, 2026 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.56 ▼ -46.8% | $-0.66 — $-0.48 | 28% YoY | 5 |
| Next Q | $-0.41 ▼ -4.1% | $-0.50 — $-0.20 | 32% YoY | 5 |
| Current FY | $-1.82 ▲ +13.1% | $-2.20 — $-1.24 | -175% YoY | 5 |
| Next FY | $-2.23 ▲ +34.2% | $-2.80 — $-1.69 | -23% YoY | 5 |
Latest Reports
BULLISH
CLUSTER
8/10
Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May 28, 2026, for a tot
Jun 2, 2026
NEUTRAL
8-K
4/10
Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025, driven by lower R&D
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Carlyle Group Inc. | $7.1M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.0M | — |
| MACKENZIE FINANCIAL CORP | $1.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | DOUBLED |
| BlackRock, Inc. | $553.1K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | ORBIMED ADVISORS | BUY | $10.0M |
| May 28, 2026 | Xu Diyong | BUY | $10.0M |
| Feb 25, 2026 | Morrison Jodie | SELL | $44.7K |
| Feb 25, 2026 | Violette Shelia | SELL | $12.7K |
| Feb 25, 2026 | Kalowski Lee | SELL | $18.0K |
25 institutional holders with $13.9M total value (2,172,240 shares) as of 2026-Q1. Top holders: Carlyle, VANGUARD, MACKENZIE. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Carlyle Group Inc. | 1,102,741 | $7.1M | 50.8% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 306,401 | $2.0M | 14.1% | — |
| 3 | MACKENZIE FINANCIAL CORP | 246,304 | $1.6M | 11.3% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 206,915 | $1.3M | 9.5% | DOUBLED +110.6% |
| 5 | BlackRock, Inc. | 86,147 | $553.1K | 4.0% | ADD +43.7% |
| 6 | MARSHALL WACE, LLP | 52,440 | $336.7K | 2.4% | — |
| 7 | VANGUARD FIDUCIARY TRUST CO | 49,995 | $321.0K | 2.3% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 42,346 | $271.9K | 1.9% | ADD +48.6% |
| 9 | STATE STREET CORP | 41,514 | $266.5K | 1.9% | ADD +95.5% |
| 10 | CITADEL ADVISORS LLC | 15,481 | $99.4K | 0.7% | — |
| 11 | MORGAN STANLEY | 9,560 | $61.4K | 0.4% | ADD +74.5% |
| 12 | FMR LLC | 3,400 | $21.8K | 0.2% | NEAR_EXIT -78.8% |
| 13 | ROYAL BANK OF CANADA | 2,744 | $18.0K | 0.1% | DOUBLED +274.3% |
| 14 | FEDERATED HERMES, INC. | 2,273 | $14.6K | 0.1% | DOUBLED +443.1% |
| 15 | Vanguard Global Advisers, LLC | 1,915 | $12.3K | 0.1% | — |
| 16 | Rockefeller Capital Management L.P. | 577 | $3.7K | 0.0% | — |
| 17 | JONES FINANCIAL COMPANIES LLLP | 500 | $3.6K | 0.0% | — |
| 18 | Russell Investments Group, Ltd. | 454 | $2.9K | 0.0% | TRIM -30.3% |
| 19 | NISA INVESTMENT ADVISORS, LLC | 166 | $1.1K | 0.0% | TRIM -71.8% |
| 20 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 111 | $713.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 59,932 | 86,147 | +43.7% | $553.1K | 2026-Q1 |
| STATE STREET CORP | ADD | 21,237 | 41,514 | +95.5% | $266.5K | 2026-Q1 |
| MORGAN STANLEY | ADD | 5,478 | 9,560 | +74.5% | $61.4K | 2026-Q1 |
| CWM, LLC | TRIM | 54 | 39 | -27.8% | $250.00 | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 219 | 54 | -75.3% | — | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 47,300 | 99,600 | +110.6% | $330.7K | 2025-Q4 |
| BlackRock, Inc. | TRIM | 93,005 | 59,932 | -35.6% | $199.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 31,506 | 46,825 | +48.6% | $155.5K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 11,343 | 5,478 | -51.7% | $18.2K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 15,867 | 3,364 | -78.8% | $11.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,525 | 1,035 | -32.1% | $3.4K | 2025-Q4 |
| Allworth Financial LP | NEAR_EXIT | 610 | 98 | -83.9% | $326.00 | 2025-Q4 |
| HRT FINANCIAL LP | ADD | 14,836 | 24,698 | +66.5% | $81.00 | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 4,769 | 219 | -95.4% | — | 2025-Q3 |
| BlackRock, Inc. | TRIM | 178,677 | 93,005 | -47.9% | $184.2K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 77,000 | 47,300 | -38.6% | $93.7K | 2025-Q3 |
| FMR LLC | TRIM | 42,439 | 15,867 | -62.6% | $31.4K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 18,648 | 11,343 | -39.2% | $22.5K | 2025-Q3 |
| UBS Group AG | TRIM | 12,576 | 5,246 | -58.3% | $10.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 2,198 | 1,525 | -30.6% | $3.0K | 2025-Q3 |
| Allworth Financial LP | DOUBLED | 16 | 610 | +3712.5% | $1.2K | 2025-Q3 |
| NISA INVESTMENT ADVISORS, LLC | TRIM | 589 | 166 | -71.8% | $329.00 | 2025-Q3 |
| STATE STREET CORP | NEAR_EXIT | 137,498 | 26,937 | -80.4% | $40.1K | 2025-Q2 |
| UBS Group AG | TRIM | 33,431 | 12,576 | -62.4% | $18.7K | 2025-Q2 |
| Mariner, LLC | NEAR_EXIT | 84,780 | 11,780 | -86.1% | $17.6K | 2025-Q2 |
8 unique insiders with 11 transactions. Net insider value: $19.9M ($20.0M bought, $75.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | ORBIMED ADVISORS LLC | Director | BUY | 1,250,000 | $8.00 | $10.0M |
| May 28, 2026 | Xu Diyong | Director | BUY | 1,250,000 | $8.00 | $10.0M |
| Feb 25, 2026 | Morrison Jodie Pope | CEO | SELL | 9,896 | $4.51 | $44.7K |
| Feb 25, 2026 | Violette Shelia M. | Chief Scientific Officer | SELL | 2,815 | $4.51 | $12.7K |
| Feb 25, 2026 | Kalowski Lee | CFO and President | SELL | 3,995 | $4.51 | $18.0K |
| Feb 24, 2026 | Violette Shelia M. | Chief Scientific Officer | AWARD | 37,500 | — | — |
| Feb 24, 2026 | Kalowski Lee | CFO and President | AWARD | 53,250 | — | — |
| Feb 24, 2026 | Morrison Jodie Pope | CEO | AWARD | 132,000 | — | — |
| Jan 15, 2026 | Lundberg Sven Ante | Director | AWARD | 20,363 | $2.75 | $56.0K |
| Jan 15, 2026 | LAPORTE KATHLEEN | Director | AWARD | 23,272 | $2.75 | $64.0K |
| Jan 15, 2026 | GRAYZEL DAVID S. | Director | AWARD | 16,363 | $2.75 | $45.0K |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 5.5/10.
BULLISH
CLUSTER
8/10
Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May
Jun 2, 2026
NEUTRAL
8-K
4/10
Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025,
May 5, 2026
BEARISH
8-K
6/10
Q32 Bio Inc. has filed an additional prospectus supplement to raise up to $75 million through its at
Apr 24, 2026
BEARISH
424B5
6/10
Q32 Bio Inc. is conducting an at-the-market (ATM) equity offering of up to $75 million in common sto
Apr 24, 2026
BEARISH
424B5
6/10
Q32 Bio Inc. (QTTB) has filed a 424B5 prospectus supplement to register the at-the-market offering o
Mar 27, 2026
NEUTRAL
CLUSTER
3/10
Three executive insiders at Q32 Bio Inc. (QTTB) sold shares in a coordinated open-market transaction
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 3 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.25 mean target
+12.7% upside
Buy (3.00)
$10.00 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $12.64 |
| Target Low | $10.00 |
| Target Mean | $14.25 |
| Target Median | $13.50 |
| Target High | $20.00 |
| # Analysts | 4 |
| Recommendation | Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.56 | $-0.66 | $-0.48 | 28.5% | -46.8% | — | $0.0B | 0.0% | 5 |
| Next Q 2026-09-30 |
$-0.41 | $-0.50 | $-0.20 | 32.3% | -4.1% | — | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-1.82 | $-2.20 | $-1.24 | -175.0% | +13.1% | 1↑ 0↓ | $0.0B | -98.1% | 5 |
| Next FY 2027-12-31 |
$-2.23 | $-2.80 | $-1.69 | -22.8% | +34.2% | 2↑ 0↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.558 | |
| 7d ago | $-0.583 | +0.025 |
| 30d ago | $-0.380 | -0.178 |
| 60d ago | $-0.380 | -0.178 |
| 90d ago | $0.000 | -0.558 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | Mizuho | INITIATE | — | Outperform |
| May 18, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 25, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 3 | 3 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 3 | 3 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
short_volume
Short Volume: QTTB — 69.8% short (0.5M / 0.7M)
Short: 486,236 | Exempt: 0 | TRF Vol: 696,739 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: QTTB — 61.0% short (0.3M / 0.5M)
Short: 332,756 | Exempt: 0 | TRF Vol: 545,804 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: QTTB — 57.2% short (0.3M / 0.5M)
Short: 308,123 | Exempt: 7,261 | TRF Vol: 538,539 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
QTTB Q1 2026 Earnings Scheduled — 2026-05-07
Apr 2, 2026
Clinical Trial
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 2, 2026
clinical_trial_readout
T-60d Trial Readout: bempikibart (ADX-914) (Phase 2)
Trial: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Sponsor: Q32 Bio Inc.
Phase:
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: bempikibart (ADX-914) (Phase 2)
Trial: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Sponsor: Q32 Bio Inc.
Phase:
Mar 17, 2026
earnings_calendar
QTTB Q4 2025 Earnings After Market Close — 2026-03-17